Intracorporeal Anastomosis Versus Extracorporeal Anastomosis for Left Colon Cancer

Prior treatment

• Patients who need to undergo combined organ resection or robot-assisted colectomy.
• Patients who are receiving preoperative neoadjuvant therapy.
• Patients who need combined organ resection as determined by intraoperative exploration.

Other illness

• Have a history of malignant colorectal tumor or have metastatic or multiple carcinoma.
• Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc. who need emergency surgery.
• Patients with severe psychiatric illness.
• Patients who have a history of taking hormonal drugs.
• Patients with other non-tumor diseases that prevent them from continuing to receive this treatment regimen.
• Patients who need emergency surgical resection due to intestinal obstruction, intestinal perforation, intestinal bleeding, etc. after being enrolled in the study.

Lab values

• Cardiopulmonary dysfunction (NYHA cardiac function classification II-IV), liver dysfunction (MELD score greater than 12), or kidney dysfunction (serum creatinine above the upper limit of normal);
• Diabetic patients whose blood sugar cannot be controlled to be within 6.1 - 8.3 mmol/L.
• Patients with other clinical and laboratory conditions that are considered by researchers as inappropriate for participating in this trial.
  • Exit criteria

Other

• ASA grade ≥ IV and/or ECOG performance status score \> 2.
• Pregnant or lactating women.
• Patients with distant metastasis confirmed by intraoperative exploration or postoperative pathology, including liver, pelvic cavity, ovary, peritoneum, distant lymph node metastasis, etc.
• Patients who request to withdraw from this study cohort for various reasons after being enrolled in the study, or who cannot complete the study plan and follow-up for various reasons.

• age between 18 and 80 years;
• histologically or cytologically confirmed left-sided colon cancer (distal transverse colon, left colic flexure, descending colon, or proximal sigmoid colon);
• clinical stage T1-4a, N0-2, and M0;
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
• suitable for laparoscopic colectomy;
• no previous systemic chemotherapy or radiotherapy;
• willing to provide written informed consent and comply with the research procedures.